Guangzhou Innogen Pharmaceutical (HKG:2591) expects a net loss of about 341.4 million yuan for 2025, widening from a loss of about 174.7 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.
The pharmaceutical company said the wider loss was mainly due to higher research and development spending and increased selling and distribution expenses related to the product's launch and sales expansion.
The company is expected to announce financial results on March 23.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments